Deerfield Management Company, L.P. (Series C) Cogent Biosciences, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.37 Billion
- Q3 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 9,053,118 shares of COGT stock, worth $304 Million. This represents 2.42% of its overall portfolio holdings.
Number of Shares
9,053,118
Previous 2,640,215
242.89%
Holding current value
$304 Million
Previous $19 Million
585.81%
% of portfolio
2.42%
Previous 0.44%
Shares
12 transactions
Others Institutions Holding COGT
# of Institutions
214Shares Held
133MCall Options Held
999KPut Options Held
429K-
Fairmount Funds Management LLC Philadelphia, PA9MShares$302 Million28.14% of portfolio
-
Kynam Capital Management, LP Princeton, NJ7.89MShares$265 Million9.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.76MShares$260 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$244 Million0.0% of portfolio
-
Commodore Capital LP New York, NY7.25MShares$243 Million6.65% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $2.21B
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...